Browsing Tag
Boehringer Ingelheim
23 posts
Palatin Technologies to raise $15.8m in public offering; NYSE relisting expected Nov 12
Palatin Technologies regains NYSE American compliance and secures $15.8M for its oral MC4R obesity drug. Find out how the relisting and IND impact its biotech trajectory.
Why OSE Immunotherapeutics stock is moving after Marc Le Bozec replaces Nicolas Poirier as CEO
OSE Immunotherapeutics ousts CEO Nicolas Poirier, names Marc Le Bozec interim chief and launches a strategic review. See what it means for investors.
Why Leo Pharma’s completed Spevigo deal with Boehringer could reshape rare skin disease care
Leo Pharma completes its acquisition of Spevigo® from Boehringer Ingelheim. Learn how this rare disease drug strengthens its dermatology growth strategy.
Thermo Fisher wins FDA approval for next-generation sequencing companion diagnostic tied to new HER2-mutant NSCLC therapy
Thermo Fisher wins FDA approval for its Oncomine Dx Target Test as a companion diagnostic for Boehringer Ingelheim’s new HER2-mutant NSCLC therapy.
Lupin Limited (NSE: LUPIN) gains on dual U.S. approvals for nasal spray and ophthalmic gel
Lupin Limited gains on U.S. nasal spray launch and FDA approval for ophthalmic gel. Find out how this could reshape its U.S. generics growth strategy.
Cognizant Q1 2025 earnings: AI strategy, strategic deals, and capital returns signal strong start to the year
Find out how Cognizant is accelerating growth through AI-powered services and global deals in its strong Q1 2025 earnings report.
Lupin acquires diabetes trademarks from Boehringer Ingelheim to bolster treatment portfolio
Lupin Limited, a global pharmaceutical leader based in Mumbai, has announced the acquisition of three anti-diabetes trademarks—GIBTULIO, GIBTULIO…
AI revolution in lung disease care: Brainomix and Boehringer Ingelheim forge game-changing partnership
Brainomix, a leader in artificial intelligence (AI) imaging solutions, has announced a partnership with the German pharmaceutical giant…
Boehringer Ingelheim’s SENVELGO gets EU marketing authorization for feline diabetes treatment
The European Commission has granted marketing authorization to Boehringer Ingelheim for SENVELGO (active ingredient: velagliflozin), a groundbreaking development…
Boehringer Ingelheim expands oncology portfolio with T3 Pharma acquisition
Boehringer Ingelheim announced its acquisition of T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech company specializing in immuno-oncology,…